Live Breaking News & Updates on Profectus biosciences inc

Stay informed with the latest breaking news from Profectus biosciences inc on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Profectus biosciences inc and stay connected to the pulse of your community

Human Papillomavirus Vaccine Global Market Report 2023: Increasing Cases of Human Papillomavirus Diseases Drive Growth

/PRNewswire/ -- The "Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Valence...

United-states , Dublin , Ireland , India , America , Bharat , Laura-wood , E-st-office-hours-call , Pan-american-health-organization , Research-methodology , Johnson , Xenetic-biosciences-inc

Combined Sales of Biodefense are estimated to Cross US$ 32.99 billion by 2033 Rise in Sales for Vacc

It is estimated that the Biodefense Market is anticipated to reach US$ 32.99 billion by 2033 after being valued at US$ 16.31 billion in 2023. This market is projected to expand at a CAGR of 7.3% during the analysis period. The growing demand for vaccines, drugs, and medical devices provides companies with opportunit...

Delaware , United-states , Xoma , Xizang , China , New-york , America , Cleveland-biolabs , Ichor-medical-systems-inc , Appili-therapeutics-inc , Elusys-therapeutics-inc , Department-of-defense

Biodefense Market Sales are Estimated to Cross US$ 32.99

In recent years, the biodefense market has experienced significant growth due to increased government funding for biodefense programs and growing public...

China , Dubai , Dubayy , United-arab-emirates , United-states , India , United-kingdom , Xoma , Xizang , America , Ichor-holdings-ltd

Biodefense Market is Expected to Witness Huge Demand by Size, Share, CAGR, Future Innovations and Forecast 2028

Biodefense Market Industry Analysis, New Trends, and Innovations, Future Forecast 2028

Australia , United-states , Brazil , China , Austria , Russia , Mexico , India , Egypt , Netherlands , Kuwait , Italy

DVIDS - News - Nipah virus, much deadlier than SARS-CoV-2, could be the next pandemic

8
For years, scientists have warned the Nipah virus -- a brain-swelling disease 75 times more deadly than COVID -- could be the next pandemic. Knowing that this fruit bat-borne virus has the potential to trigger an epidemic, researchers at the Uniformed Services University (USU) have long studied the virus and recently reported on the development of a single-dose vaccine that, in preclinical trials, has proven effective against it as early as seven days after immunization.
The Nipah virus first emerged in the late 1990s, causing serious disease outbreaks in humans and livestock in Malaysia and Singapore. More frequent and recent Nipah outbreaks in Bangladesh, the Philippines and India have resulted in acute respiratory distress syndrome and encephalitis, person-to-person transmission, and greater than 75 percent case fatality rates among humans (the SARS-CoV-2 coronavirus that causes COVID and a fatality rate of less than one percent). Much like Nipah, the closely-related Hendra virus was also discovered in the 1990s in Australia where it repeatedly causes fatal infections in horses and exposure risk to people. Like Nipah, Hendra has also been found naturally in several species of fruit bats (flying foxes). The National Institutes of Health (NIH) and Centers for Disease Control and Prevention have classified Nipah and Hendra as biothreat agents, and the U.S. Department of Agriculture characterized them as agriculture threat agents.

Kerala , India , Australia , Malaysia , Bangladesh , Philippines , Singapore , Thomas-geisbert , Antony-dimitrov , Christopher-broder , Centers-for-disease , Uniformed-services-university

Single-Dose Nipah, Hendra Vaccine for Humans Effective 7 Days After Immunization

Single-Dose Nipah, Hendra Vaccine for Humans Effective 7 Days After Immunization
Newswise — Bethesda, MD— A vaccine for use against the deadly Nipah and Hendra viruses has demonstrated effectiveness in preclinical studies as early as 7 days following a single immunization, according to a new study, "A Single Dose Investigational Subunit Vaccine for Human Use against Nipah virus and Hendra virus," published in the journal,
npj Vaccines, online February 8, 2021.
A collaborative group of investigators from the Uniformed Services University (USU), the University of Texas Medical Branch (UTMB) and Galveston National Laboratory (GNL), and Profectus BioSciences, Inc. (now Auro Vaccines LLC), carried out two preclinical studies of a Nipah and Hendra virus vaccine. Their results show that a subunit vaccine formulated for use in humans is effective as early as a week after the vaccination is administered.

Australia , Malaysia , Bangladesh , India , Singapore , Thomas-geisbert , Christopher-broder , Antonys-dimitrov , Centers-for-disease , Uniformed-services-university , Us-department-of-agriculture , National-institutes-of-health